title: [Consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in psoriatic arthritis].
abstract: OBJECTIVE
  Due to the amount and quality variability regarding the use of biologic therapy (BT) in psoriatic arthritis (PsA) patients, the Spanish Society of Rheumatology (SER) has promoted the generation of recommendations based on the best evidence available. These recommendations should serve as reference to rheumatologists and those involved in the treatment of patients with PsA, who are using, or about to use BT.
  
  
  METHODS
  Recommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and degree of recommendation was classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique.
  
  
  RESULTS
  We have produced recommendations for the use of TB currently available for PsA in our country. These recommendations include disease assessment, treatment objectives, therapeutic scheme and switching.
  
  
  CONCLUSIONS
  We present an update on the SER recommendations for the use of BT in patients with PsA.
authors.affiliation: Servicio de Reumatología, Hospital Universitario A Coruña, A Coruña, España.
authors.forename: Jose Luis
authors.initials: JL
authors.lastname: Fernández Sueiro
authors.forename: Xavier
authors.initials: X
authors.lastname: Juanola Roura
authors.forename: Juan de Dios
authors.initials: Jde D
authors.lastname: Cañete Crespillo
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Torre Alonso
authors.forename: Rosario
authors.initials: R
authors.lastname: García de Vicuña
authors.forename: Rubén
authors.initials: R
authors.lastname: Queiro Silva
authors.forename: Rafael
authors.initials: R
authors.lastname: Ariza Ariza
authors.forename: Enrique
authors.initials: E
authors.lastname: Batlle Gualda
authors.forename: Estíbaliz
authors.initials: E
authors.lastname: Loza Santamaría
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy*; D001691:Biological Therapy; D003697:Delphi Technique; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab; D000069285:Infliximab; D000068800:Etanercept